PMID- 34007203
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1178-7066 (Print)
IS  - 1178-7066 (Electronic)
IS  - 1178-7066 (Linking)
VI  - 14
DP  - 2021
TI  - Circulating Level of Monocyte Chemoattractant Protein-1 and Risk of Coronary 
      Artery Disease: A Case-Control and Mendelian Randomization Study.
PG  - 553-559
LID - 10.2147/PGPM.S303362 [doi]
AB  - BACKGROUND: Coronary artery disease (CAD) ranks the leading cause of death 
      worldwide, and inflammation has been implicated in all stages of CAD and is 
      considered to contribute to the pathophysiological basis of atherogenesis. 
      METHODS: Here, we implemented a case-control study and a two-sample Mendelian 
      randomization (MR) study to explore the associations between CAD risk and genetic 
      predisposition to circulating level of monocyte chemoattractant protein-1 (MCP1), 
      the most important regulator of monocyte trafficking. RESULTS: In case-control 
      study, we found circulating level of MCP1 was significantly associated with 
      increased risk of CAD (OR for per quartile increment: 1.33, 95% CI: 1.19-1.49, 
      P<0.001). Further, genetically predicted higher level of MCP1 was significantly 
      associated with higher risk of CAD (OR for 1-SD increase: 1.05, 95% CIs: 
      1.02-1.08, P value: 0.002) in MR analysis. Sensitivity analyses were also 
      conducted to validate the main findings, and we also did not detect any 
      directional pleiotropy effects using the MR Egger intercept test (P=0.831). 
      CONCLUSION: To sum up, our study suggested that increased CAD risk was associated 
      with a predisposition to higher level of MCP1. Additional insight into the 
      contribution of MCP1 to the occurrence of CAD is still needed.
CI  - (c) 2021 Li et al.
FAU - Li, Jing
AU  - Li J
AD  - Department of Health Care, Jinan People's Hospital Affiliated to Shandong First 
      Medical University, Jinan, Shandong Province, 271100, People's Republic of China.
FAU - Zhang, Yanqun
AU  - Zhang Y
AD  - Department of Health Care, Jinan People's Hospital Affiliated to Shandong First 
      Medical University, Jinan, Shandong Province, 271100, People's Republic of China.
FAU - Guo, Xue
AU  - Guo X
AD  - Department of Health Care, Jinan People's Hospital Affiliated to Shandong First 
      Medical University, Jinan, Shandong Province, 271100, People's Republic of China.
FAU - Wu, Yuanyuan
AU  - Wu Y
AD  - Department of Health Care, Jinan People's Hospital Affiliated to Shandong First 
      Medical University, Jinan, Shandong Province, 271100, People's Republic of China.
FAU - Huang, Ruo
AU  - Huang R
AD  - Department of Health Care, Jinan People's Hospital Affiliated to Shandong First 
      Medical University, Jinan, Shandong Province, 271100, People's Republic of China.
FAU - Han, Xia
AU  - Han X
AD  - Department of Cardiology, Jinan People's Hospital Affiliated to Shandong First 
      Medical University, Jinan, Shandong Province, 271100, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210511
PL  - New Zealand
TA  - Pharmgenomics Pers Med
JT  - Pharmacogenomics and personalized medicine
JID - 101514107
PMC - PMC8124014
OTO - NOTNLM
OT  - MCP1
OT  - Mendelian randomization
OT  - case-control
OT  - coronary artery disease
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/05/20 06:00
MHDA- 2021/05/20 06:01
PMCR- 2021/05/11
CRDT- 2021/05/19 06:45
PHST- 2021/01/25 00:00 [received]
PHST- 2021/03/19 00:00 [accepted]
PHST- 2021/05/19 06:45 [entrez]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/05/20 06:01 [medline]
PHST- 2021/05/11 00:00 [pmc-release]
AID - 303362 [pii]
AID - 10.2147/PGPM.S303362 [doi]
PST - epublish
SO  - Pharmgenomics Pers Med. 2021 May 11;14:553-559. doi: 10.2147/PGPM.S303362. 
      eCollection 2021.